What AI could mean to healthcare’s supply chain

While the loudest buzz around AI in healthcare continues to emanate from clinical and research quarters, an easily overlooked subpopulation is watching with keen interest: hospital supply-chain executives and the vendor reps who call on them.

An article posted this week in the Journal of Healthcare Contracting, which covers developments in that industry, summarizes the advance of AI in healthcare to date and offers a supply chain-specific perspective.

The magazine’s primary source for the piece is Zach Rothstein, vice president of technology and regulatory affairs for AdvaMed, the medical device trade association.

As FDA grapples with issues related to AI’s changing of the device-regulation landscape, he suggests, supply chain execs could help.

“A lot of these [AI development] companies are small, and they’re trying to figure out how to get into the market,” Rothstein says. “They may be sophisticated at developing software, but many are new to the healthcare market.”

By interacting with such companies, supply chain executives might be able to help them understand what the market needs, suggests the author of the article, which describes noteworthy examples of AI-based devices already cleared by the FDA.

The piece also takes up some worthwhile questions, including one on what’s ahead and another that asks: “What if AI makes a mistake?”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.